Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...
For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results